marketcaparena
Search

    AMRX

    Amneal Pharmaceuticals, Inc.

    Company overview

    Market capitalization
    $6.55B
    Employees
    8,700
    Latest publication
    2026-09-29
    About Amneal Pharmaceuticals, Inc.

    Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20222022-09-30 · USDQ1 20182018-03-31 · USDQ4 20172017-12-31 · USDQ3 20172017-09-30 · USDQ2 20172017-06-30 · USDQ1 20172017-03-31 · USDQ4 20162016-12-31 · USD
    Total Revenue796,197,000USD545,557,000USD275,189,000USD293,369,000USD254,733,000USD259,871,000USD225,681,000USD298,576,000USD
    Cost Of Revenue461,689,000USD351,327,000USD130,594,000USD141,953,000USD119,720,000USD136,138,000USD115,832,000USD121,926,000USD
    Gross Profit334,508,000USD194,230,000USD144,595,000USD151,416,000USD135,013,000USD123,733,000USD109,849,000USD176,650,000USD
    Research Development39,017,000USD51,646,000USD48,785,000USD46,226,000USD48,016,000USD52,110,000USD39,419,000USD43,513,000USD
    Selling General Administrative148,722,000USD98,646,000USD25,121,000USD26,966,000USD27,440,000USD26,938,000USD27,440,000USD31,126,000USD
    Total Operating Expenses204,739,000USD149,877,000USD73,906,000USD73,192,000USD75,456,000USD79,048,000USD52,424,000USD100,794,000USD
    Operating Income129,769,000USD44,353,000USD63,554,000USD79,019,000USD78,753,000USD44,603,000USD42,728,000USD92,297,000USD
    Total Other Income Expense Net-58,779,000USD-42,173,000USD-11,538,000USD-16,944,000USD-52,369,000USD-5,003,000USD536,000USD-36,513,000USD
    Income Before Tax70,990,000USD2,180,000USD52,016,000USD62,075,000USD26,384,000USD39,600,000USD43,264,000USD55,959,000USD
    Income Tax Expense1,376,000USD4,570,000USD364,000USD-119,000USD-738,000USD1,852,000USD1,003,000USD1,550,000USD
    Net Income69,614,000USD-2,689,000USD51,535,000USD61,569,000USD26,780,000USD37,446,000USD42,261,000USD53,898,000USD
    Minority Interest11,952,000USD299,000USD10,634,000USD10,157,000USD812,000USD7,721,000USD-8,533,000USD9,345,000USD
    Net Income Applicable To Common Shares57,662,000USD-2,689,000USD-19,104,000USD167,648,000USD-31,761,000USD97,704,000USD-65,943,000USD53,898,000USD
    Interest Expense—42,391,000USD21,051,000USD19,956,000USD19,218,000USD17,726,000USD25,633,000USD19,897,000USD
    Net Interest Income—-42,391,000USD——————
    Tax Provision—4,570,000USD——————
    Net Income From Continuing Ops—-2,390,000USD-250,090,000USD169,325,000USD-32,081,000USD98,638,000USD-66,557,000USD54,409,000USD
    Ebit—44,571,000USD70,689,000USD102,224,000USD59,557,000USD44,603,000USD42,728,000USD92,297,000USD
    Ebitda—106,179,000USD85,440,000USD115,066,000USD71,515,000USD44,607,000USD53,328,000USD102,011,000USD
    Depreciation And Amortization—61,608,000USD14,751,000USD12,842,000USD11,958,000USD4,000USD10,600,000USD9,714,000USD
    Reconciled Depreciation—61,608,000USD14,751,000USD12,842,000USD11,958,000USD———
    Non Operating Income Net Other—218,000USD——————
    Discontinued Operations——0USD0USD0USD0USD0USD0USD
    Unclassified Operating Expenses——————-14,435,000USD26,155,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20172017-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USDFY 20142014-12-31 · USD
    Total Revenue1,033,654,000USD1,018,225,000USD866,280,000USD785,623,000USD
    Cost Of Revenue507,476,000USD420,770,000USD367,054,000USD335,989,000USD
    Gross Profit526,178,000USD597,455,000USD499,226,000USD449,634,000USD
    Research Development191,938,000USD204,747,000USD136,870,000USD106,735,000USD
    Selling General Administrative109,046,000USD118,757,000USD201,287,000USD84,615,000USD
    Total Operating Expenses300,984,000USD323,504,000USD277,809,000USD239,639,000USD
    Operating Income245,103,000USD284,881,000USD227,230,000USD222,942,000USD
    Interest Income53,412,000USD40,419,000USD39,226,000USD—
    Interest Expense71,061,000USD55,283,000USD0USD0USD
    Net Interest Income-71,061,000USD-55,283,000USD——
    Income Before Tax171,323,000USD214,821,000USD175,582,000USD179,331,000USD
    Income Tax Expense1,998,000USD5,395,000USD4,951,000USD1,513,000USD
    Tax Provision1,998,000USD5,395,000USD20,371,000USD—
    Net Income167,648,000USD207,378,000USD169,451,000USD176,928,000USD
    Net Income From Continuing Ops169,325,000USD209,426,000USD170,631,000USD177,818,000USD
    Ebit225,194,000USD273,951,000USD227,230,000USD222,942,000USD
    Ebitda271,130,000USD306,967,000USD252,677,000USD243,284,000USD
    Depreciation And Amortization45,936,000USD33,016,000USD25,447,000USD20,342,000USD
    Reconciled Depreciation45,936,000USD———
    Total Other Income Expense Net-73,780,000USD-70,060,000USD-60,576,000USD-39,244,000USD
    Minority Interest10,157,000USD9,345,000USD8,270,000USD8,270,000USD
    Net Income Applicable To Common Shares167,648,000USD207,378,000USD38,997,000USD176,928,000USD
    Unclassified Operating Expenses——-60,348,000USD48,289,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets3,776,348,000USD3,540,218,000USD3,678,280,000USD3,599,874,000USD3,422,788,000USD3,365,249,000USD3,501,445,000USD3,460,978,000USD
    Cash And Equivalents127,637,000USD———————
    Total Current Assets1,947,029,000USD1,797,907,000USD1,911,181,000USD1,838,478,000USD1,584,692,000USD1,510,450,000USD1,587,806,000USD1,513,294,000USD
    Other Current Assets112,011,000USD55,981,000USD54,134,000USD98,592,000USD45,268,000USD49,536,000USD87,201,000USD56,702,000USD
    Other Non Current Assets80,669,000USD———————
    Total Liabilities3,659,368,000USD———————
    Total Current Liabilities883,187,000USD728,049,000USD881,633,000USD862,106,000USD1,107,134,000USD1,075,824,000USD1,129,771,000USD1,095,209,000USD
    Total Stockholder Equity33,024,000USD-45,411,000USD-70,794,000USD-109,458,000USD-112,533,000USD-131,667,000USD-109,267,000USD-93,432,000USD
    Total Equity Including Noncontrolling Interest116,980,000USD———————
    Short Long Term Debt11,922,000USD6,200,000USD6,761,000USD7,202,000USD321,175,000USD321,790,000USD324,213,000USD364,692,000USD
    Long Term Debt2,564,335,000USD2,565,558,000USD2,565,115,000USD2,566,500,000USD2,146,403,000USD2,153,979,000USD2,161,790,000USD2,169,607,000USD
    Inventory677,954,000USD641,618,000USD606,302,000USD614,500,000USD608,973,000USD601,433,000USD612,454,000USD596,359,000USD
    Property Plant Equipment Net456,877,000USD558,762,000USD550,326,000USD538,055,000USD546,294,000USD522,748,000USD523,693,000USD532,897,000USD
    Goodwill593,499,000USD———————
    Intangible Assets587,830,000USD534,869,000USD563,498,000USD587,938,000USD649,547,000USD689,136,000USD732,377,000USD780,189,000USD
    Retained Earnings-415,087,000USD-472,749,000USD-535,005,000USD-570,081,000USD-572,450,000USD-594,867,000USD-607,062,000USD-575,981,000USD
    Accumulated Other Comprehensive Income-100,666,000USD-112,151,000USD-110,729,000USD-105,883,000USD-97,431,000USD-85,740,000USD-65,509,999USD-73,782,000USD
    Total Liab—3,586,187,000USD3,672,317,000USD3,709,829,000USD3,469,519,000USD3,424,638,000USD3,545,983,000USD3,494,658,000USD
    Other Current Liab—478,889,000USD605,386,000USD574,277,000USD104,911,000USD545,748,000USD529,672,000USD479,188,000USD
    Common Stock—3,190,000USD3,146,000USD3,143,000USD3,140,000USD3,134,000USD3,099,000USD3,098,000USD
    Capital Stock—3,190,000USD3,146,000USD3,143,000USD3,140,000USD3,134,000USD3,099,000USD3,098,000USD
    Good Will—593,800,000USD595,470,000USD595,945,000USD597,406,000USD597,497,000USD597,436,000USD598,324,000USD
    Cash—197,656,000USD310,871,000USD201,249,000USD81,186,000USD59,187,000USD110,552,000USD74,006,000USD
    Cash And Short Term Investments—197,656,000USD310,871,000USD201,249,000USD81,186,000USD59,187,000USD112,420,000USD74,006,000USD
    Net Debt—2,498,831,000USD2,425,603,000USD2,484,475,000USD2,500,707,000USD2,520,314,000USD2,482,587,000USD2,570,655,000USD
    Short Term Debt—21,485,000USD21,576,000USD21,471,000USD335,406,000USD337,544,000USD340,255,000USD381,021,000USD
    Short Long Term Debt Total—2,696,487,000USD2,736,474,000USD2,685,724,000USD2,581,893,000USD2,579,501,000USD2,593,139,000USD2,644,661,000USD
    Net Receivables—902,652,000USD939,874,000USD924,137,000USD849,265,000USD800,294,000USD775,731,000USD786,227,000USD
    Accounts Payable—227,675,000USD254,671,000USD266,358,000USD666,817,000USD192,532,000USD259,844,000USD235,000,000USD
    Property Plant Equipment Gross—558,762,000USD1,156,496,000USD538,055,000USD546,294,000USD522,748,000USD1,087,213,000USD532,897,000USD
    Common Stock Shares Outstanding—328,933,000shares324,805,000shares324,754,000shares322,363,000shares323,961,000shares309,850,000shares309,647,000shares
    Non Current Assets Total—1,742,311,000USD1,767,099,000USD1,761,396,000USD1,838,096,000USD1,854,799,000USD1,913,639,000USD1,947,684,000USD
    Non Current Liabilities Total—2,858,138,000USD2,790,684,000USD2,847,723,000USD2,362,385,000USD2,348,814,000USD2,416,212,000USD2,399,449,000USD
    Non Current Liabilities Other—71,253,000USD92,728,000USD88,534,000USD82,672,000USD80,086,000USD94,051,000USD90,999,000USD
    Non Currrent Assets Other—42,152,000USD49,981,000USD39,458,000USD25,927,000USD19,027,000USD24,212,000USD18,335,000USD
    Net Working Capital—1,069,858,000USD1,029,548,000USD976,372,000USD477,558,000USD434,626,000USD458,035,000USD418,085,000USD
    Unclassified Non Current Liabilities—221,327,000USD132,841,000USD192,689,000USD133,310,000USD114,749,000USD160,371,000USD138,843,000USD
    Unclassified Equity—533,109,000USD568,648,000USD560,220,000USD551,068,000USD542,672,000USD557,106,999USD550,135,000USD
    Unclassified Non Current Assets————18,922,000USD26,391,000USD35,921,000USD—
    Unclassified Current Liabilities————-321,175,000USD-321,790,000USD-324,213,000USD-364,692,000USD
    Short Term Investments——————1,868,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets3,678,280,000USD3,501,445,000USD3,472,569,000USD3,799,341,000USD3,939,664,000USD4,006,033,000USD3,665,890,000USD4,352,736,000USD
    Intangible Assets563,498,000USD732,377,000USD890,423,000USD1,096,093,000USD1,166,922,000USD1,304,626,000USD1,382,753,000USD1,654,969,000USD
    Other Current Assets54,134,000USD87,201,000USD57,077,000USD111,495,000USD88,189,000USD78,821,000USD72,433,000USD98,143,000USD
    Total Liab3,672,317,000USD3,545,983,000USD3,411,265,000USD3,590,413,000USD3,572,691,000USD3,649,297,000USD3,319,102,000USD3,456,373,000USD
    Total Stockholder Equity-70,794,000USD-109,267,000USD19,781,000USD298,421,000USD360,340,000USD303,270,999USD232,010,000USD896,363,000USD
    Other Current Liab605,386,000USD529,672,000USD76,988,000USD481,318,000USD497,599,000USD465,287,999USD410,431,000USD417,289,000USD
    Common Stock3,146,000USD3,099,000USD3,066,000USD3,036,000USD3,014,000USD2,997,000USD2,992,000USD2,987,000USD
    Capital Stock3,146,000USD3,099,000USD3,066,000USD3,036,000USD3,014,000USD2,997,000USD2,992,000USD2,987,000USD
    Retained Earnings-535,005,000USD-607,062,000USD-490,176,000USD-406,183,000USD-276,197,000USD-286,821,000USD-377,880,000USD-20,920,000USD
    Good Will595,470,000USD597,436,000USD598,629,000USD598,853,000USD593,017,000USD522,813,999USD419,504,000USD426,226,000USD
    Cash310,871,000USD110,552,000USD91,542,000USD25,976,000USD247,790,000USD341,378,000USD151,197,000USD213,394,000USD
    Cash And Short Term Investments310,871,000USD112,420,000USD93,742,000USD27,797,000USD247,790,000USD343,074,000USD152,320,000USD213,394,000USD
    Total Current Assets1,911,181,000USD1,587,806,000USD1,377,863,000USD1,411,818,000USD1,520,108,000USD1,551,539,000USD1,210,210,000USD1,286,644,000USD
    Total Current Liabilities881,633,000USD1,129,771,000USD846,595,000USD752,800,000USD677,243,000USD676,902,000USD550,406,000USD553,850,000USD
    Net Debt2,425,603,000USD2,482,587,000USD2,658,981,000USD2,819,159,000USD2,628,266,000USD2,657,445,000USD2,618,739,000USD2,478,002,000USD
    Short Term Debt21,576,000USD340,255,000USD227,624,000USD104,639,000USD46,037,000USD57,474,000USD36,954,000USD21,715,000USD
    Short Long Term Debt6,761,000USD324,213,000USD213,125,000USD89,961,000USD30,614,000USD45,228,000USD21,479,000USD21,449,000USD
    Short Long Term Debt Total2,736,474,000USD2,593,139,000USD2,750,523,000USD2,845,135,000USD2,876,056,000USD2,998,823,000USD2,769,936,000USD2,691,396,000USD
    Long Term Debt2,565,115,000USD2,161,790,000USD2,427,451,000USD2,591,981,000USD2,680,053,000USD2,735,264,000USD2,609,046,000USD2,630,598,000USD
    Net Receivables939,874,000USD775,731,000USD645,660,000USD741,791,000USD694,740,000USD638,995,000USD604,390,000USD565,322,000USD
    Inventory606,302,000USD612,454,000USD581,384,000USD530,735,000USD489,389,000USD490,649,000USD381,067,000USD457,219,000USD
    Accounts Payable254,671,000USD259,844,000USD143,572,000USD166,843,000USD131,084,000USD154,140,000USD103,021,000USD114,846,000USD
    Property Plant Equipment Net550,326,000USD523,693,000USD550,137,000USD589,360,000USD639,003,000USD604,710,000USD620,595,000USD544,146,000USD
    Property Plant Equipment Gross1,156,496,000USD1,087,213,000USD1,058,164,000USD589,360,000USD639,003,000USD604,710,000USD609,153,000USD544,146,000USD
    Accumulated Other Comprehensive Income-110,729,000USD-65,509,999USD-32,349,000USD9,938,999USD-24,827,000USD-41,317,999USD-68,000USD-7,755,000USD
    Common Stock Shares Outstanding324,805,000shares308,978,000shares176,136,000shares150,944,000shares151,821,000shares148,913,000shares132,106,000shares127,252,000shares
    Non Current Assets Total1,767,099,000USD1,913,639,000USD2,094,706,000USD2,387,523,000USD2,419,556,000USD2,454,494,000USD2,455,680,000USD3,066,092,000USD
    Non Current Liabilities Total2,790,684,000USD2,416,212,000USD2,564,670,000USD2,837,613,000USD2,895,448,000USD2,972,395,000USD2,768,696,000USD2,902,523,000USD
    Non Current Liabilities Other92,728,000USD94,051,000USD8,215,000USD245,632,000USD198,488,000USD237,131,000USD39,583,000USD231,664,000USD
    Non Currrent Assets Other49,981,000USD24,212,000USD18,428,000USD17,631,000USD20,614,000USD22,344,000USD16,455,000USD67,592,000USD
    Net Working Capital1,029,548,000USD458,035,000USD531,268,000USD659,018,000USD842,865,000USD874,637,000USD659,804,000USD732,794,000USD
    Unclassified Non Current Liabilities132,841,000USD160,371,000USD129,004,000USD-99,323,000USD-33,218,000USD-89,915,000USD81,254,000USD-196,607,000USD
    Unclassified Equity568,648,000USD557,106,999USD536,174,000USD688,593,001USD655,336,000USD625,415,998USD603,974,000USD919,064,000USD
    Short Term Investments—1,868,000USD2,200,000USD1,821,000USD1,174,000USD1,696,000USD1,123,000USD2,142,000USD
    Unclassified Non Current Assets—35,921,000USD37,089,000USD67,955,000USD-473,696,000USD-149,299,999USD—-67,592,000USD
    Unclassified Current Liabilities—-324,213,000USD-213,125,000USD-89,961,000USD-28,091,000USD-45,227,999USD-21,479,000USD-38,878,000USD
    Current Deferred Revenue——398,411,000USD————17,429,000USD
    Deferred Long Term Liab———2,206,000USD1,603,000USD2,648,000USD3,099,000USD4,026,000USD
    Other Liab———97,117,000USD48,522,000USD87,267,000USD35,714,000USD232,842,000USD
    Other Assets———17,631,000USD473,696,000USD149,300,000USD16,455,000USD440,751,000USD
    Net Tangible Assets———-1,371,576,000USD-1,382,692,000USD-1,512,365,000USD-1,570,247,000USD-1,576,445,000USD
    Long Term Investments——————16,373,000USD—
    Unclassified Current Assets———————-49,576,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation64,900,000USD
    Stock Based Compensation19,208,000USD
    Other Non Cash Items-6,596,000USD
    Change To Account Receivables-125,765,000USD
    Change To Inventory-124,150,000USD
    Change To Liabilities-57,918,000USD
    Change In Working Capital-331,983,000USD
    Operating Cash Flow-47,987,000USD
    Capital Expenditures-38,872,000USD
    Unclassified Investing Cash Flow-105,580,000USD
    Investing Cash Flow-144,452,000USD
    Net Debt Issuance134,673,000USD
    Net Common Stock Issuance-44,481,000USD
    Other Financing Activities-400,000USD
    Unclassified Financing Cash Flow-69,486,000USD
    Financing Cash Flow20,306,000USD
    Effect Of Forex Changes On Cash-1,187,000USD
    Change In Cash-173,320,000USD
    End Cash Flow139,619,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income78,000,000USD49,573,000USD18,132,000USD35,610,000USD24,618,000USD-20,742,000USD11,757,000USD5,994,000USD
    Depreciation43,191,000USD49,227,000USD54,073,000USD60,113,000USD60,159,000USD66,130,000USD58,961,000USD63,021,000USD
    Stock Based Compensation8,816,000USD8,202,000USD8,219,000USD8,274,000USD7,258,000USD7,210,000USD7,112,000USD6,724,000USD
    Other Non Cash Items83,357,000USD35,603,000USD112,119,000USD14,930,000USD21,753,000USD43,625,000USD21,176,000USD80,487,000USD
    Change To Account Receivables43,957,000USD-9,521,000USD-77,335,000USD-54,869,000USD21,148,000USD-27,641,000USD21,957,000USD-100,670,000USD
    Change To Inventory-54,959,000USD-20,180,000USD-30,807,000USD-22,776,000USD-13,263,000USD-51,985,000USD-43,098,000USD-23,247,000USD
    Change In Working Capital-190,082,000USD-12,290,000USD-50,738,000USD-35,108,000USD-106,380,000USD21,855,000USD42,768,000USD-116,569,000USD
    Total Cash From Operating Activities-28,725,000USD130,315,000USD118,450,000USD83,819,000USD7,408,000USD118,078,000USD141,774,000USD39,657,000USD
    Capital Expenditures-13,860,000USD-43,169,000USD-15,050,000USD-26,502,000USD-18,322,000USD-23,064,000USD-20,712,000USD-10,704,000USD
    Free Cash Flow-42,585,000USD87,146,000USD103,400,000USD57,317,000USD-10,914,000USD95,014,000USD121,062,000USD28,952,999USD
    Total Cashflows From Investing Activities-21,710,000USD-45,454,000USD-22,464,000USD-26,547,000USD-17,798,000USD-16,059,000USD-20,712,000USD-6,465,000USD
    Net Borrowings-6,169,000USD-6,124,000USD140,442,000USD-15,548,000USD-17,528,000USD-55,535,000USD-87,210,000USD—
    Total Cash From Financing Activities-57,073,000USD-10,120,000USD59,443,000USD-41,687,000USD-39,166,000USD-61,204,000USD-92,346,000USD-35,086,000USD
    Change In Cash-109,041,000USD74,895,000USD154,790,000USD15,416,000USD-50,026,000USD40,075,000USD28,723,000USD-1,995,000USD
    Begin Period Cash Flow310,871,000USD235,976,000USD81,186,000USD65,769,999USD118,420,000USD78,345,000USD49,622,000USD51,617,000USD
    End Period Cash Flow201,830,000USD310,871,000USD235,976,000USD81,186,000USD68,394,000USD118,420,000USD78,345,000USD49,622,000USD
    Other Cashflows From Financing Activities-50,942,000USD-4,549,000USD-8,423,999USD-25,079,000USD-21,707,000USD-5,669,000USD-4,942,000USD-7,931,000USD
    Unclassified Operating Cash Flow-52,007,000USD—-23,355,000USD—————
    Unclassified Investing Cash Flow-7,850,000USD-2,285,000USD22,464,000USD26,502,000USD22,958,000USD23,664,000USD24,312,000USD6,465,000USD
    Investments——-22,464,000USD-26,547,000USD-17,798,000USD-16,059,000USD-20,712,000USD-6,465,000USD
    Other Cashflows From Investing Activities——-7,414,000USD—-4,636,000USD-600,000USD-3,600,000USD4,239,000USD
    Unclassified Financing Cash Flow——-72,575,001USD—21,708,000USD——-26,996,000USD
    Sale Purchase Of Stock———-189,000USD-21,639,000USD-387,000USD-194,000USD-159,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income72,057,000USD-73,876,000USD-48,722,000USD-254,789,000USD10,624,000USD91,059,000USD-603,573,000USD-201,303,000USD
    Depreciation223,572,000USD236,191,000USD229,400,000USD240,175,000USD233,406,000USD244,065,000USD207,235,000USD137,403,000USD
    Stock Based Compensation31,953,000USD27,768,000USD26,822,000USD31,847,000USD28,412,000USD20,750,000USD21,679,000USD167,597,000USD
    Other Non Cash Items216,926,000USD109,084,000USD185,263,000USD107,812,000USD131,382,999USD84,752,000USD124,865,000USD148,962,000USD
    Change To Account Receivables-120,566,000USD-162,155,000USD125,799,000USD-79,071,000USD-16,309,999USD16,787,000USD-133,665,000USD89,084,000USD
    Change To Inventory-87,026,000USD-130,530,000USD-126,182,000USD-102,396,000USD-49,015,000USD-113,782,000USD-20,393,000USD-42,875,000USD
    Change In Working Capital-204,516,000USD-4,068,000USD-47,186,000USD-59,945,000USD-133,592,999USD-61,625,000USD-120,217,000USD7,010,000USD
    Total Cash From Operating Activities339,992,000USD295,099,000USD345,577,000USD65,100,000USD241,820,000USD379,001,000USD1,705,000USD250,230,000USD
    Capital Expenditures-70,063,000USD-74,990,000USD-69,189,000USD-90,595,000USD-47,728,000USD-61,836,000USD-97,431,000USD-97,088,000USD
    Free Cash Flow269,929,000USD220,109,000USD276,388,000USD-25,495,000USD194,092,000USD317,164,999USD-95,726,000USD153,142,000USD
    Total Cashflows From Investing Activities-112,263,000USD-62,996,000USD-69,189,000USD-174,309,000USD-194,182,000USD-317,546,000USD-19,580,000USD-396,378,000USD
    Net Borrowings101,242,000USD-185,118,000USD22,652,000USD83,337,000USD-1,000,000USD175,898,000USD-27,000,000USD486,335,000USD
    Total Cash From Financing Activities-31,530,000USD-211,791,000USD-212,573,000USD-106,620,000USD-138,122,000USD131,806,999USD-45,833,000USD287,675,000USD
    Change In Cash194,519,000USD19,313,000USD63,880,000USD-221,512,000USD-90,382,000USD194,299,000USD-65,957,000USD140,857,000USD
    Begin Period Cash Flow118,420,000USD99,107,000USD35,227,000USD256,739,000USD347,121,000USD152,822,000USD218,779,000USD77,922,000USD
    End Period Cash Flow312,939,000USD118,420,000USD99,107,000USD35,227,000USD256,738,999USD347,121,000USD152,822,000USD218,779,000USD
    Other Cashflows From Investing Activities-42,200,000USD-14,650,000USD-22,388,000USD-40,800,000USD-3,211,000USD-4,350,000USD-7,233,000USD25,344,000USD
    Other Cashflows From Financing Activities-59,759,000USD-26,673,000USD-235,225,000USD-68,348,000USD-59,796,000USD-10,318,000USD-16,563,000USD-70,374,000USD
    Unclassified Financing Cash Flow-73,013,000USD7,952,000USD2,378,000USD-114,467,000USD-74,662,000USD-32,910,001USD-1,344,000USD62,330,000USD
    Investments—-62,996,000USD-69,189,000USD-174,309,000USD-194,182,000USD-317,546,000USD-19,580,000USD-396,378,000USD
    Sale Purchase Of Stock—-7,952,000USD-2,378,000USD-3,571,000USD-2,664,000USD-863,000USD-926,000USD-7,618,000USD
    Unclassified Investing Cash Flow—89,640,000USD91,577,000USD131,395,000USD50,939,000USD66,186,000USD104,664,000USD71,744,000USD
    Change To Liabilities———111,640,000USD-46,287,000USD1,953,000USD-5,029,000USD-69,325,000USD
    Dividends Paid———-3,571,000USD——0USD-182,998,000USD
    Cash And Cash Equivalents Changes———-215,829,000USD-90,484,000USD193,262,000USD-63,708,000USD141,527,000USD
    Unclassified Operating Cash Flow————-28,412,000USD—371,716,000USD-9,439,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31SegmentAffordable Medicines423,237,000USD0001723128-26-000020
    Q1 2026Quarterly · 2026-03-31SegmentAmneal Specialty Pharma133,265,000USD0001723128-26-000020
    Q1 2026Quarterly · 2026-03-31SegmentAv KARE166,017,000USD0001723128-26-000020
    FY 2025Yearly · 2025-12-31SegmentAffordable Medicines1,745,524,000USD0001723128-26-000011
    FY 2025Yearly · 2025-12-31SegmentAv KARE744,728,000USD0001723128-26-000011
    FY 2025Yearly · 2025-12-31SegmentSpecialty528,508,000USD0001723128-26-000011
    Q1 2025Quarterly · 2025-03-31SegmentAffordable Medicines414,708,000USD0001723128-26-000020
    Q1 2025Quarterly · 2025-03-31SegmentAmneal Specialty Pharma108,297,000USD0001723128-26-000020
    Q1 2025Quarterly · 2025-03-31SegmentAv KARE172,415,000USD0001723128-26-000020
    FY 2024Yearly · 2024-12-31SegmentAffordable Medicines1,685,263,000USD0001723128-26-000011
    FY 2024Yearly · 2024-12-31SegmentAv KARE662,945,000USD0001723128-26-000011
    FY 2024Yearly · 2024-12-31SegmentSpecialty445,749,000USD0001723128-26-000011
    FY 2023Yearly · 2023-12-31SegmentAffordable Medicines1,471,401,000USD0001723128-26-000011
    FY 2023Yearly · 2023-12-31SegmentAv KARE531,749,000USD0001723128-26-000011
    FY 2023Yearly · 2023-12-31SegmentSpecialty390,457,000USD0001723128-26-000011
    FY 2022Yearly · 2022-12-31SegmentAffordable Medicines1,432,073,000USD0001723128-25-000012
    FY 2022Yearly · 2022-12-31SegmentAv KARE406,110,000USD0001723128-25-000012
    FY 2022Yearly · 2022-12-31SegmentSpecialty374,121,000USD0001723128-25-000012
    FY 2021Yearly · 2021-12-31SegmentAv KARE349,012,000USD0001723128-24-000014
    FY 2021Yearly · 2021-12-31SegmentGenerics1,366,338,000USD0001723128-24-000014
    FY 2021Yearly · 2021-12-31SegmentSpecialty378,319,000USD0001723128-24-000014
    FY 2019Yearly · 2019-12-31SegmentAv Kare0USD0001723128-22-000006
    FY 2019Yearly · 2019-12-31SegmentGenerics1,308,843,000USD0001723128-22-000006
    FY 2019Yearly · 2019-12-31SegmentOther317,530,000USD0001723128-22-000006
    FY 2019Yearly · 2019-12-31GeographyInternational20,600,000USD0001564590-20-008179
    FY 2019Yearly · 2019-12-31GeographyOther2,859,000USD0001564590-20-008179
    FY 2019Yearly · 2019-12-31GeographyUnited States1,602,914,000USD0001564590-20-008179
    Q3 2019Quarterly · 2019-09-30SegmentAmneal Specialty Pharma87,262,000USD0001564590-19-041240
    Q3 2019Quarterly · 2019-09-30SegmentGenerics291,021,000USD0001564590-19-041240
    Q2 2019Quarterly · 2019-06-30SegmentAmneal Specialty Pharma69,578,000USD0001723128-19-000111
    Q2 2019Quarterly · 2019-06-30SegmentGenerics335,064,000USD0001723128-19-000111
    Q1 2019Quarterly · 2019-03-31SegmentAmneal Specialty Pharma63,643,000USD0001723128-19-000079
    Q1 2019Quarterly · 2019-03-31SegmentGenerics382,477,000USD0001723128-19-000079
    FY 2018Yearly · 2018-12-31SegmentAv Kare0USD0001723128-21-000013
    FY 2018Yearly · 2018-12-31SegmentGenerics1,439,031,000USD0001723128-21-000013
    FY 2018Yearly · 2018-12-31SegmentOther223,960,000USD0001723128-21-000013
    FY 2018Yearly · 2018-12-31GeographyInternational59,700,000USD0001564590-20-008179
    FY 2018Yearly · 2018-12-31GeographyUnited States1,602,997,000USD0001564590-20-008179
    Q3 2018Quarterly · 2018-09-30SegmentAmneal Specialty Pharma85,312,000USD0001564590-19-041240
    Q3 2018Quarterly · 2018-09-30SegmentGenerics391,175,000USD0001564590-19-041240
    Q2 2018Quarterly · 2018-06-30SegmentAmneal Specialty Pharma52,017,000USD0001723128-19-000111
    Q2 2018Quarterly · 2018-06-30SegmentGenerics361,770,000USD0001723128-19-000111
    Q1 2018Quarterly · 2018-03-31SegmentAmneal Specialty Pharma0USD0001723128-19-000079
    Q1 2018Quarterly · 2018-03-31SegmentGenerics275,189,000USD0001723128-19-000079
    FY 2017Yearly · 2017-12-31SegmentGenerics1,033,654,000USD0001723128-19-000028
    FY 2017Yearly · 2017-12-31SegmentSpecialty0USD0001723128-19-000028
    FY 2017Yearly · 2017-12-31GeographyInternational74,536,000USD0001564590-20-008179
    FY 2017Yearly · 2017-12-31GeographyOther12,522,000USD0001564590-20-008179
    FY 2017Yearly · 2017-12-31GeographyUnited States946,596,000USD0001564590-20-008179

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.